Congenital dyshaematopoietic anemia is more commonly called congenital dyserythropoietic anemia, or CDA. It is a rare inherited blood disorder. In this disease, the bone marrow makes red blood cells in an abnormal way. Many young red blood cells do not grow and mature properly. Because of this, the body has too few healthy red blood cells, and anemia happens. The word congenital means a person is born with it. The word dyserythropoietic means the body forms red blood cells in an abnormal way. In simple words, CDA is a condition where the “red blood cell factory” does not work correctly from birth. [1][2][3]
The standard medical name for the condition you asked about is congenital dyserythropoietic anemia (CDA). CDA is a rare inherited blood disorder in which the bone marrow makes red blood cells in an abnormal way, so many cells do not mature properly. This causes chronic anemia, tiredness, jaundice, enlarged spleen or liver, and often iron overload, even in some people who do not receive many transfusions. [1][2]
CDA is not one single disease. It is a group of related inherited anemias, including CDA type I, II, III, and IV, with different genes and different severity. Because of that, treatment is not the same for every patient. Some people need only monitoring, while others need transfusions, iron chelation, interferon, surgery, or stem cell transplant. [1][2][3]
Other Names
Other names used for this condition are CDA, congenital dyserythropoiesis, inherited dyserythropoietic anemia, and in some cases the type names such as CDA type I, CDA type II, CDA type III, and CDA type IV. Some related conditions are also called transcription factor-related CDA or X-linked dyserythropoietic anemia with thrombocytopenia when the genetic problem affects blood cell control proteins. These names are used because CDA is not just one disease. It is a group of related inherited disorders with similar red blood cell production problems. [1][3][4]
Types
Type I is usually linked to changes in CDAN1 or CDIN1/C15orf41. It often causes moderate to severe anemia, jaundice, and a large spleen. Some people also develop iron overload. [2][4]
Type II is the most common form. It is usually caused by changes in SEC23B. It often causes anemia, jaundice, splenomegaly, gallstones, and later iron overload. [1][3][5]
Type III is very rare. It is linked to changes in KIF23 in many families. It is known for very large abnormal erythroblasts in bone marrow. Some patients may also have eye problems. [3][4]
Type IV is very rare and is linked to changes in KLF1. It can cause severe anemia from early life because KLF1 is very important for red blood cell development. [3][4]
X-linked dyserythropoietic anemia with thrombocytopenia is related to changes in GATA1. In this form, the person can have anemia together with a low platelet count, because GATA1 helps control the formation of several blood cell lines. [3][4]
Causes
Because CDA is a congenital genetic disease, its true causes are mostly inherited gene changes, not lifestyle causes. There are not separate common acquired causes like in iron deficiency anemia. To give you a full and honest list, below are the main proven genetic causes and disease mechanisms that can lead to CDA or CDA-like congenital dyserythropoiesis. [1][3][4]
1. CDAN1 gene mutation can cause CDA type I. This gene helps normal red blood cell development. When it is altered, erythroblasts do not mature the right way. [2][4]
2. CDIN1 (C15orf41) gene mutation can also cause CDA type I. This gene works with cell growth and nuclear control in erythroid cells. A defect can disturb final red cell formation. [4][6]
3. SEC23B gene mutation causes CDA type II in most patients. This gene helps transport proteins inside cells. When it fails, red blood cell precursors become abnormal. [1][3][5]
4. KIF23 gene mutation can cause CDA type III. KIF23 helps cell division. When it is altered, erythroblasts may become very large and multinucleated. [3][4]
5. KLF1 gene mutation can cause CDA type IV. KLF1 is a key transcription factor for red blood cell genes. A defect can severely disturb erythropoiesis. [3][4]
6. GATA1 gene mutation can cause an X-linked dyserythropoietic anemia with thrombocytopenia. This gene is important for both red blood cells and platelets. [3][4]
7. Autosomal recessive inheritance is a common cause pattern in CDA I and CDA II. This means a child inherits one abnormal gene copy from each parent. [1][3][4]
8. Autosomal dominant inheritance can cause some forms such as many CDA III cases and some CDA IV cases. In this pattern, one abnormal copy may be enough to cause disease. [3][4]
9. X-linked inheritance causes some GATA1-related disease. Boys are often more severely affected because they have only one X chromosome. [3][4]
10. Ineffective erythropoiesis is a key disease mechanism. The bone marrow makes many young red cells, but many die before becoming mature working cells. [3][6]
11. Abnormal erythroblast maturation is another direct mechanism. The cells stay immature or develop in a distorted way. [1][3]
12. Abnormal nuclear structure in erythroblasts is especially important in CDA I. The nucleus inside the young red cell can look unusual because normal chromatin organization is disturbed. [2][6]
13. Defective membrane or protein trafficking inside cells is central in CDA II. If protein transport is abnormal, erythroblasts cannot develop normal cell structure. [3][5]
14. Defective cell division can produce binucleated or multinucleated erythroblasts. This is a major mechanism in some CDA forms, especially CDA III. [3][6]
15. Disturbed transcription factor control is seen in KLF1- and GATA1-related disease. This means the master switches for blood cell development are not working well. [3][4]
16. Increased red cell destruction can add to anemia in CDA. The body may remove the abnormal red cells too early. [3][7]
17. Chronic iron over-absorption is not the starting genetic cause, but it is part of disease biology. Ineffective erythropoiesis can tell the body to absorb too much iron. [2][3]
18. Unknown or not-yet-identified gene defects can also be a cause. Reviews note that some patients with clear CDA features still do not have a fully identified mutation. [4][6]
19. Rare familial founder mutations in specific populations can cause CDA in some families. This means one old inherited mutation is shared by many related affected people. [6]
20. De novo mutation can occasionally be the cause. This means a new gene change appears in the affected person even when there is no known family history. This is less common than inherited transmission but can happen in genetic disease. [3][4]
Symptoms
1. Tiredness is one of the most common symptoms. It happens because the blood carries less oxygen when healthy red blood cells are low. [1][2][3]
2. Weakness is common for the same reason. Muscles and tissues do not receive enough oxygen, so the person feels low energy. [1][3]
3. Pale skin can happen when hemoglobin is low. The skin, lips, and inner eyelids may look less pink than usual. [1][2]
4. Jaundice means yellow color in the eyes or skin. It happens because bilirubin rises when red blood cells break down faster than normal. [2][3][5]
5. Enlarged spleen can happen because the spleen removes abnormal blood cells. Over time it may become larger than normal. [2][3][5]
6. Enlarged liver may occur in some patients, especially in more severe disease or early life. [2][3]
7. Shortness of breath can happen during walking, climbing, or exercise because the body is trying to get more oxygen. [1][3]
8. Fast heartbeat may happen because the heart works harder to deliver oxygen to the tissues. [3][8]
9. Dizziness can happen when anemia lowers oxygen delivery to the brain. [3][8]
10. Headache is another possible symptom of anemia and reduced oxygen carrying capacity. [3][8]
11. Poor growth in infants or children may be seen in some patients with chronic anemia. [2][3]
12. Gallstones can develop, especially in CDA II, because long-term hemolysis changes bile chemistry. [3][5]
13. Abdominal fullness or discomfort may happen because the spleen or liver is enlarged. [3][7]
14. Iron overload symptoms may appear later. Too much iron can damage organs such as the liver, heart, and hormone glands. [2][3][7]
15. Severe fetal or newborn anemia can occur in some severe cases, especially certain CDA I or CDA IV presentations. This may show before birth or soon after birth. [2][3]
Diagnostic Tests
Physical Exam
1. General appearance and pallor check is a basic but important test. The doctor looks for pale skin, pale lips, and pale conjunctiva. This can suggest anemia, although it does not prove CDA by itself. [1][3]
2. Jaundice inspection means looking at the eyes and skin for yellow color. This suggests increased bilirubin from red cell breakdown and supports a hemolytic or ineffective erythropoiesis picture. [2][3]
3. Spleen examination is done by feeling the left upper abdomen. A large spleen is common in many CDA patients and is an important clinical clue. [2][3][5]
4. Liver examination is done by feeling the right upper abdomen. Liver enlargement can happen, especially in more severe or long-standing disease. [2][3]
Manual Test
5. Family history review is very important. The doctor asks about anemia, jaundice, gallstones, transfusions, or similar disease in relatives because CDA is inherited. [1][3][4]
6. Growth and developmental assessment is used in children. Long-term anemia can affect growth, feeding, activity, and general development. [2][3]
7. Detailed symptom history is a manual clinical test. The doctor asks when tiredness started, whether jaundice comes and goes, and whether transfusions were needed. This helps separate congenital disease from new acquired disease. [2][3]
8. Genetic counseling assessment is also part of evaluation. It helps identify inheritance pattern, affected relatives, and reproductive risk in the family. [2][4]
Lab and Pathological Tests
9. Complete blood count (CBC) is one of the main tests. It measures hemoglobin, hematocrit, and red cell indices. It confirms anemia and helps show whether the red cells are larger or smaller than normal. [2][3]
10. Reticulocyte count is very useful. In CDA, the reticulocyte response is often lower than expected for the degree of anemia because red cell production is ineffective. [3][6]
11. Peripheral blood smear lets a specialist look at blood cells under a microscope. It may show abnormal shapes, size differences, or basophilic stippling. This supports but does not by itself confirm CDA. [3][6]
12. Bilirubin test helps check red cell breakdown. Indirect bilirubin can be high in CDA because abnormal red cells are destroyed. [2][3]
13. Lactate dehydrogenase (LDH) may be elevated. This is another sign that cells are being damaged or destroyed. [3][7]
14. Haptoglobin may be low when hemolysis is present. It is a supportive blood test in the workup of chronic anemia with red cell destruction. [3][7]
15. Iron studies include ferritin, transferrin saturation, and serum iron. These tests are important because many CDA patients develop iron overload, even without many transfusions. [2][3]
16. Bone marrow aspiration is a key diagnostic test. It shows erythroid hyperplasia and abnormal erythroblasts. In simple words, it lets doctors inspect the red blood cell factory directly. [3][6]
17. Bone marrow biopsy provides tissue architecture and can help confirm abnormal erythropoiesis. It is often used with marrow aspiration. [3][7]
18. Bone marrow morphology review by hematopathology is one of the most important confirmatory steps. The specialist looks for binucleated erythroblasts, multinuclear forms, and other typical patterns that help separate CDA subtypes. [3][6]
19. Electron microscopy of marrow cells is especially useful in some cases of CDA I because it can show characteristic ultrastructural nuclear changes that are hard to see on routine light microscopy. [2][9]
20. Genetic testing is now a major confirmatory test. Testing genes such as CDAN1, CDIN1/C15orf41, SEC23B, KIF23, KLF1, and GATA1 can confirm the subtype and help with family counseling. [1][3][4]
Electrodiagnostic
There is no standard electrodiagnostic test such as EMG or nerve conduction study that diagnoses CDA directly. CDA is a blood and bone marrow disease, not a nerve or muscle disease. So in an evidence-based workup, electrodiagnostic tests are usually not core tests for diagnosis. [3][4]
Imaging Tests
1. Abdominal ultrasound is commonly used to look for enlarged spleen, enlarged liver, and gallstones. These are common complications in CDA, especially CDA II. [3][5]
2. MRI for liver iron is used to check iron overload. This is very important because excess iron can silently build up over time. [2][3]
3. Cardiac MRI for heart iron may be used in patients with significant iron overload or many transfusions. It helps detect iron damage in the heart before severe symptoms appear. [2][3]
4. Prenatal ultrasound may detect severe fetal anemia or hydrops in rare severe cases before birth. [2][3]
Doctors do not diagnose CDA from one test alone. The diagnosis usually needs clinical signs, blood tests, bone marrow findings, and often genetic confirmation together. It is also important to rule out other causes of anemia such as thalassemia, hemolytic anemia, vitamin deficiency, myelodysplastic syndrome, and other inherited red blood cell disorders. [3][6][7]
Non-pharmacological treatments
1. Regular hematology follow-up. CDA needs long-term care with a blood specialist because the disease can slowly cause anemia problems, iron overload, spleen enlargement, and gallstones. Regular follow-up helps doctors catch complications early and change treatment before organ damage happens. The purpose is prevention and early action. The mechanism is simple: repeated clinical review plus blood tests and imaging reduce missed complications. [1][3]
2. Genetic confirmation and family counseling. Genetic testing helps confirm the exact CDA type and can guide prognosis, family planning, and screening of relatives. The purpose is diagnostic accuracy. The mechanism is that finding the responsible gene explains why red cell production is abnormal and helps separate CDA from thalassemia, hemolytic anemia, or marrow disorders. [2][3]
3. Scheduled complete blood count monitoring. Regular CBC checks help measure hemoglobin, reticulocytes, and anemia severity over time. The purpose is to know when the patient is stable and when more treatment is needed. The mechanism is trend tracking: doctors can see whether the marrow is failing further, whether transfusions are becoming necessary, or whether treatment is working. [1][4]
4. Iron overload surveillance. Many CDA patients absorb excess iron even without many transfusions, so ferritin and liver iron monitoring are very important. The purpose is to protect the liver, heart, and endocrine organs. The mechanism is early detection of iron buildup before symptoms become severe. [1][2]
5. Liver MRI for iron measurement. MRI is a noninvasive way to estimate liver iron concentration. The purpose is better iron assessment than ferritin alone, because ferritin can rise for other reasons too. The mechanism is tissue-based measurement that helps guide when chelation should start or intensify. [6][7]
6. Heart monitoring when iron burden is high. In patients with long-standing iron overload, heart checks such as echocardiography or cardiac MRI may be needed. The purpose is to find early heart injury from iron. The mechanism is screening for organ complications before heart failure or rhythm problems appear. [2][3]
7. Gallbladder ultrasound surveillance. CDA can increase bilirubin turnover and raise the risk of pigment gallstones. The purpose is to detect stones before they cause pain, infection, or bile duct blockage. The mechanism is imaging-based early diagnosis, especially in patients with jaundice or abdominal pain. [4][13]
8. Spleen size monitoring. Splenomegaly is common in CDA and can worsen anemia by trapping blood cells. The purpose is to decide whether observation is enough or whether surgery may be discussed later. The mechanism is serial physical examination and ultrasound to track enlargement. [1][4]
9. Red blood cell transfusion support when needed. Although transfusion is a procedure rather than a drug, it is one of the most important supportive treatments in severe CDA. The purpose is to improve oxygen delivery and reduce symptoms of severe anemia. The mechanism is direct replacement of deficient red cells. [3][4]
10. Careful transfusion matching. Repeated transfusions can cause alloimmunization and transfusion reactions. The purpose is safer long-term transfusion care. The mechanism is matching blood more carefully, reducing antibody formation and future transfusion difficulty. [3][5]
11. Avoiding unnecessary iron intake. Patients with CDA and iron overload should not take extra iron unless a doctor proves iron deficiency. The purpose is to reduce further iron burden. The mechanism is limiting external iron exposure in a disease already prone to excess absorption. [1][3]
12. Balanced high-quality nutrition. Good nutrition cannot cure CDA, but it supports growth, immunity, and recovery from chronic anemia. The purpose is overall body support. The mechanism is providing protein, vitamins, and minerals needed for tissue repair and blood production, while avoiding harmful excesses such as unneeded iron. [2][13]
13. Vaccination review, especially before or after splenectomy. People without a functioning spleen have a higher risk of severe infection. The purpose is infection prevention. The mechanism is immune priming against encapsulated bacteria such as pneumococcus, meningococcus, and Hib. [5]
14. Fever action plan. CDA itself does not always suppress white cells, but splenectomy, severe disease, or transplant can change infection risk. The purpose is fast treatment of possible severe infection. The mechanism is early medical contact when fever appears instead of waiting at home. [5]
15. Growth and bone health monitoring in children. Chronic anemia and chronic illness can affect growth and development. The purpose is to protect normal childhood development. The mechanism is repeated assessment of weight, height, puberty, and bone health so problems are treated earlier. [1][2]
16. Pregnancy planning with specialists. Some CDA forms can be severe in pregnancy or even present before birth. The purpose is safer pregnancy for mother and baby. The mechanism is coordinated care between hematology, genetics, and obstetrics before conception and during pregnancy. [1][3]
17. Physical activity adapted to symptoms. Light-to-moderate activity can support strength and wellbeing, but heavy exertion may worsen fatigue in severe anemia. The purpose is energy preservation with safe conditioning. The mechanism is matching activity level to oxygen-carrying capacity. [2][3]
18. School and work accommodations. Chronic fatigue and hospital visits can affect education and employment. The purpose is function and quality of life. The mechanism is reducing physical overload and allowing medical access without constant crisis. [2]
19. Psychological support. Rare chronic diseases often cause stress, fear, and social isolation. The purpose is mental wellbeing. The mechanism is counseling, family education, and coping support, which improve adherence and daily function. [2][3]
20. Hematopoietic stem cell transplant evaluation in severe disease. For selected severe patients, transplant may be curative. The purpose is long-term cure rather than lifelong supportive care. The mechanism is replacement of the abnormal blood-forming marrow with healthy donor stem cells. [5]
Drug treatments actually used in CDA care
1. Deferasirox. Deferasirox is an oral iron chelator used when CDA causes transfusional or clinically important iron overload. It is not a cure for CDA, but it is one of the most important medicines in long-term care. FDA labeling supports its use for chronic iron overload due to blood transfusions. Typical dosing is weight-based and individualized by the hematologist. The purpose is to lower body iron. The mechanism is binding excess iron so it can be removed from the body. Important side effects include kidney injury, liver injury, and stomach upset. [6]
2. Deferoxamine. Deferoxamine is an injectable iron chelator for chronic iron overload. FDA labeling describes subcutaneous or intravenous treatment, often with weight-based dosing over many hours using a pump. The purpose is iron removal when ferritin or organ iron rises too high. The mechanism is chemical binding of free iron and increased excretion. Important side effects include infusion burden, visual or hearing toxicity, growth issues in children with heavy use, and allergic reactions. [7]
3. Deferiprone. Deferiprone is another iron chelator. FDA labeling supports its use for transfusional iron overload in thalassemia and other anemias in pediatric patients, and clinicians may consider it when CDA-related iron overload is difficult to control. The purpose is iron reduction. The mechanism is oral iron binding with excretion. Important side effects include nausea, joint pain, liver enzyme rise, and the serious risk of neutropenia or agranulocytosis, so blood count monitoring is essential. [8]
4. Interferon alfa for CDA type I. Long-term alpha interferon has been reported to improve anemia and reduce iron loading in CDA type I, but not all CDA types respond. The purpose is to reduce transfusion need and improve ineffective erythropoiesis in selected patients. The mechanism is not fully understood, but it appears to improve red cell production in some CDA-I patients. Side effects may include flu-like illness, mood changes, liver test abnormalities, and low blood counts. [1][3]
5. Peginterferon alfa-2a. Peginterferon alfa-2a is a longer-acting interferon formulation; FDA labeling provides weekly dosing schedules for its approved uses, and CDA specialists sometimes adapt interferon-based therapy in selected CDA-I cases. The purpose is a more practical interferon schedule in responders. The mechanism is prolonged interferon signaling. Side effects can include fever, fatigue, depression, liver toxicity, and cytopenias. This is specialist-guided and not routine for every CDA patient. [9][1]
6. Epoetin alfa. Epoetin alfa is an erythropoiesis-stimulating agent. It is FDA-approved for several anemias, though not specifically for CDA. In practice, it may occasionally be tried in selected anemia settings if the clinician believes marrow stimulation could help. The purpose is to support red cell production. The mechanism is acting like erythropoietin. Risks include hypertension, clotting events, and overly rapid hemoglobin rise. Evidence in CDA is limited, so this is not a standard universal therapy. [10][3]
7. Darbepoetin alfa. Darbepoetin alfa is another erythropoiesis-stimulating agent with a longer action than epoetin alfa. FDA labeling supports use in certain approved anemia settings, but not CDA specifically. The purpose is similar: a trial of anemia support in very selected cases. The mechanism is prolonged erythropoietin receptor stimulation. Risks include hypertension and thrombosis. Evidence for routine benefit in CDA is weak, so only a hematologist should decide this. [11][3]
8. Folic acid. Folic acid is often recommended in chronic ineffective erythropoiesis because red cell production increases folate demand. The purpose is to prevent folate deficiency from making anemia worse. The mechanism is support of DNA synthesis in rapidly dividing blood-forming cells. It is usually well tolerated. In CDA, folate is supportive care, not a cure. [13]
9. Vitamin B12 replacement when deficient. Vitamin B12 is not a disease-specific CDA drug, but deficiency can worsen anemia and should be corrected. The purpose is to remove an additional reversible cause of poor red cell production. The mechanism is support of normal DNA synthesis and maturation of blood cells. It is most useful when a real deficiency exists. [13]
10. Ursodiol for selected gallbladder or cholestatic problems. Ursodiol is FDA-approved for biliary disease indications, not CDA itself. In CDA patients who develop gallstone-related or bile-flow problems, specialists may use it in selected situations. The purpose is bile support, not anemia correction. The mechanism is changing bile composition and flow. Side effects are usually mild but can include diarrhea. [12][4]
Dietary or supportive supplements
Folic acid, vitamin B12, and sometimes other supplements are used only when diet is poor, need is increased, or blood tests show deficiency. Evidence for many “blood booster” supplements in CDA is weak, so they should not replace medical treatment. [13][3]
The most practical supportive supplements to discuss with a doctor are: folic acid, vitamin B12, vitamin D, calcium, zinc, vitamin C in moderate food-based amounts, copper when deficient, selenium when deficient, protein supplementation for poor intake, and multivitamin support without iron. The purpose is correction of deficiency and nutritional support. The mechanism is removing extra nutritional barriers that can worsen chronic anemia or recovery. Do not take iron supplements unless a doctor confirms iron deficiency, because CDA often causes iron overload. [1][2][13]
Regenerative, immunity, or stem-cell related medicines
For this disease area, the true “regenerative” treatment is mainly stem cell transplantation, not a large established list of drugs. Medicines used around transplant or severe-care settings may include conditioning chemotherapy, infection prophylaxis, immunosuppression, growth-factor support, and transfusion support, but these are individualized and not standard CDA medicines for everyone. [5]
The six most relevant therapy categories are: interferon alfa, peginterferon alfa-2a, epoetin alfa, darbepoetin alfa, iron chelation during transplant preparation, and transplant-related immunosuppressive/supportive medicines chosen by the transplant team. Their purpose is either improving erythropoiesis, making transplant safer, or preventing transplant complications. Their mechanism depends on the category and must be tailored by specialists. [1][3][5]
Surgeries or procedures
1. Splenectomy may reduce transfusion need in selected patients with severe splenic destruction of blood cells, especially in some CDA II cases, but it also raises lifelong infection and clot risks. [4][5]
2. Cholecystectomy is done when gallstones cause pain, infection, or obstruction. The purpose is to stop repeated biliary attacks. [4]
3. Bone marrow aspiration and biopsy is a key diagnostic procedure. It helps show the classic abnormal erythroblasts that support the diagnosis. [3]
4. Central venous access placement may be needed in patients requiring repeated transfusions or complex therapy. The purpose is safer repeated vascular access. [5]
5. Hematopoietic stem cell transplantation is the major potentially curative procedure for severe CDA. It replaces diseased blood formation with donor marrow. [5]
Prevention points
There is no way to prevent the inherited gene change after birth, but complications can be reduced. The best prevention steps are: avoid unnecessary iron supplements, keep regular hematology visits, monitor ferritin and organ iron, treat severe anemia early, screen for gallstones, vaccinate before splenectomy, seek urgent care for fever after splenectomy, keep good nutrition, discuss pregnancy and family planning early, and treat iron overload before organ injury develops. [1][3][5]
When to see a doctor
See a doctor urgently if there is severe weakness, fast heartbeat, chest pain, fainting, shortness of breath, high fever, worsening jaundice, dark urine, new belly pain, or swelling. These can suggest severe anemia, hemolysis, infection, gallstone problems, or organ complications from iron overload. [2][4]
Also see a hematologist if blood tests show chronic anemia, enlarged spleen, unexplained jaundice, high ferritin, or a family history of inherited anemia. Early diagnosis matters because CDA is often mistaken for more common blood disorders. [2][3]
What to eat and what to avoid
Choose foods with good protein, folate-rich vegetables, beans, eggs, dairy or other B12 sources, fruits, whole grains, and enough calories for growth and healing. Drink enough water and keep meals balanced. [2][13]
Be careful with iron pills, high-dose iron tonics, and “blood booster” supplements unless blood tests prove iron deficiency. Avoid alcohol excess if liver iron is high. Do not start herbal products for anemia without a doctor because they may hide symptoms or stress the liver. [1][3]
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: April 01, 2025.
